

H.F.S.[®] Bioprosthesis Cardiac Valve

with High Flexible Stent

High flexibility and durability:

The flexibility in its orifice and commissures enables to absorb the stress and loading shock on critical areas of tissue produced by the constant movement of the leaflets.



Less obstruction:

The **Highly Flexible Stent** maximizes the Effective Orifice Area (EOA) allowing an increased blood flow and less obstruction.

Ease of implantation:

The final result is a stentless bioprosthesis, with an optimized valve seating due to a contoured and compliant sewing ring and the security of a harmonious distribution of its commissures' support.



FOC MEDICAL

www.focmedical.com

Calle 473 N°1171 - City Bell (B1896AAL)
Buenos Aires - Argentina
Phone/Fax: ++54221.480.0138
Authorized by ANMAT: PM 31-2



H.F.S.[®] Bioprosthesis Cardiac Valve

with High Flexible Stent



The H.F.S.[®] (High Flexible Stent) Bioprosthesis Porcine Cardiac Valve has been designed and developed with the objective of homologating its high flexibility to the biological tissues that shape the aortic root.

Treated with Glutaraldehyde, the advanced cardiac bioprosthesis possess a highly flexible metallic stent, built of Elgiloy, an alloy of cobalt, chrome, nickel and molybdenum. This material is highly biocompatible and fatigue resistant.

To an enhanced implantability to the aortic ring, the H.F.S.[®] Bioprosthesis Cardiac Valve adds the extreme flexibility of its commissures' support that are fixed to the aortic root, with the final objective of accompanying its movement during the cardiac cycle.

The function of the flexible valve orifice is to absorb the aortic movement during the cardiac cycle.

During the manufacturing process, the H.F.S.[®] Bioprosthesis Cardiac Valves are submitted to a tissue treatment phase in which they are applied a tampon solution that contains Ethylic Alcohol, Glutaraldehyde and Formaldehyde at a controlled temperature.

The treatment with this solution that contains ethanol in its formula reduces the level of cholesterol and lipids in the tissue, contributing to decrease the calcification of the prosthesis after the implant.

Built on the proven performance of Liotta Bioimplant valves, with over 10 years of clinical experience.

"Approximately 50% of the valves implanted worldwide are biological"

Models			
Mitral		Aortic	
Model	Code	Model	Code
25	HFS-25M	19	HFS-19
27	HFS-27M	21	HFS-21
29	HFS-29M	23	HFS-23
31	HFS-31M	25	HFS-25
33	HFS-33M	27	HFS-27



FOC MEDICAL

www.focmedical.com



QUALITY CERTIFICATION ISO 9001:2008

Calle 473 N°1171 - City Bell (B1896AAL)
Buenos Aires - Argentina
Phone/Fax: ++54221.480.0138
Authorized by ANMAT: PM 31-2